Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan. It also develops, produces, and markets recombinant proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops continuous renal replacement therapy, an open platform for other hemoperfusion cartridges. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone416-626-3233
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.96 million
Profitability
Miscellaneous
Employees18
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable
Spectral Medical (OTCMKTS:EDTXF) Frequently Asked Questions
What is Spectral Medical's stock symbol?
Spectral Medical trades on the OTCMKTS under the ticker symbol "EDTXF."
When is Spectral Medical's next earnings date?
Has Spectral Medical been receiving favorable news coverage?
Media coverage about EDTXF stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Spectral Medical earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Spectral Medical.
Who are some of Spectral Medical's key competitors?
Some companies that are related to Spectral Medical include OraSure Technologies (OSUR), Inovio Pharmaceuticals (INO), Alphatec (ATEC), Utah Medical Products (UTMD), Accuray (ARAY), GenMark Diagnostics (GNMK), Iradimed (IRMD), Pulse Biosciences (PLSE), SeaSpine (SPNE), Apyx Medical (APYX), Westaim (WEDXF), RenovaCare (RCAR), Soliton (SOLY), Repro-Med Systems (REPR) and Repro Med Systems (KRMD).
What other stocks do shareholders of Spectral Medical own?
Who are Spectral Medical's key executives?
Spectral Medical's management team includes the folowing people:
- Dr. Paul M. Walker, Pres, CEO & Director (Age 70)
- Dr. Gualtiero Guadagni, VP of Sales & Marketing
- Mr. Richard Wieland, Interim Chief Financial Officer
How do I buy shares of Spectral Medical?
Shares of EDTXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Spectral Medical's stock price today?
One share of EDTXF stock can currently be purchased for approximately $0.57.
How big of a company is Spectral Medical?
What is Spectral Medical's official website?
How can I contact Spectral Medical?
Spectral Medical's mailing address is 135 The West Mall Unit 2, Toronto A6, M9C 1C2. The company can be reached via phone at 416-626-3233 or via email at [email protected]
MarketBeat Community Rating for Spectral Medical (OTCMKTS EDTXF)
MarketBeat's community ratings are surveys of what our community members think about Spectral Medical and other stocks. Vote "Outperform" if you believe EDTXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDTXF will underperform the S&P 500 over the long term. You may vote once every thirty days.
